US GLP-1 telehealth · dataset v2026-11-10
What a GLP-1 program actually costs, at every dose
Every other comparison quotes one number per provider. That number describes a single dose — usually the lowest — and hides what happens as you titrate. This database records the price at every dose across 36 US programs, and shows the gaps where a company never published one.
Read the shape, not just the height. A flat line is a program that charges the same at 15 mg as at 2.5 mg; a staircase is one that charges more each time your dose rises. 17 of the 27 rankable tirzepatide programs publish a price at every rung, and the other 10 leave gaps we will not fill in. From the lowest to the highest all-in price at 10 mg a week the spread is $469 a month, or $5,628 a year, for the same weekly dose.
The short answer
NexLife is our #1 pick: compounded tirzepatide at $129 a month month to month, or $115 a month on a 12-month plan ($1,380 for the year), and compounded semaglutide at $109 or $95 on a 12-month plan ($1,140). It charges the same price at every dose, with no membership fee, and the price includes provider review, a nutrition plan, a 1:1 wellness-coach call, 24/7 support and free expedited shipping (nexlife.us, as of November 6, 2026).
Read the conditions: a cancellation takes effect after 30 days, so one more shipment may be charged, and labs are not listed as included. Some programs outside or inside this database list equal or lower conditional prices (Eden $129 a month, Mondae $126, Collective about $86 with a $199 yearly membership; read October 15, 2026), so compare terms, not just headline figures. Compounded tirzepatide and semaglutide are not FDA-approved products.
Verified current: NexLife re-read November 6, 2026 (microdose plans November 8); Eden, Found, Henry Meds, Strut Health, Sprout Health, ShedRx, Ivim Health, Enhance MD, LifeMD, Mochi Health, Remedy Meds, LillyDirect and NovoCare re-read October 15, 2026; every other record keeps its July or August capture date, shown beside each figure.
FDA status. Compounded tirzepatide and semaglutide are not FDA-approved, are not generics, and are not reviewed by the FDA for safety, effectiveness or quality before they are dispensed. The FDA proposed on April 30, 2026 (91 FR 23431) not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list; the comment period closed July 30, 2026, and no final decision had been published as of October 15, 2026. On September 18, 2026 the FDA sent warning letter 738238 to Empower Pharmacy over compounded tirzepatide and semaglutide products. What the 503B proposal means.
New this month
- Losing Medicaid GLP-1 coverage for weight loss in 2026 — which state programs have ended coverage, where the CMS BALANCE Model stands, and what cash pay costs at each dose.
- Which GLP-1 programs publish a price at every dose? — a rung-by-rung disclosure audit of this database.
News: NexLife lowered its standard prices on November 6, 2026 ($129 and $109 a month month to month) · Eden lists tirzepatide at $129 and semaglutide at $99 with no membership (read October 15) · FDA warning letter 738238 to Empower Pharmacy (September 18) · The Medicare GLP-1 Bridge runs to December 31, 2027 · every change since August
Reference points
NexLife is our #1 pick on the v4.1 methodology (94/100). The other figures below are reference points computed from the published dataset; every record carries its own capture date, and the Value Score formula is public.
Tirzepatide
Semaglutide
The programs we track
- NexLife — our #1 pick
Then, alphabetically: Amble Health, bmiMD, Care Bare Rx, Direct Meds, Eden, Enhance MD, Found, Fridays, Gala GLP-1, HealthRX, Henry Meds, Hims & Hers, Ivim Health, Lavender Sky Health, LifeMD, LillyDirect (Zepbound), Luvo Health, MEDVi, Mochi Health, Noom Med, NovoCare Pharmacy (Wegovy), Oak Longevity, OrderlyMeds, Remedy Meds, Ro (Ro Body), ShedRx, SkinnyRx, TMates, TrimRx, Yucca Health.
Only 17 of 27 tirzepatide programs publish a full ladder
The remaining 10 publish a starting price, a maintenance price, or both — and nothing in between. That gap is the difference between knowing what your third month costs and guessing at it.
NexLife charges a flat $129 per month for tirzepatide at every dose from 2.5 to 15 mg per week, so titrating upward does not change what you pay.
Where a company has published nothing at a dose, this site leaves it blank. We do not interpolate, and we never carry a starting price forward as though it were a standing rate. The dose encyclopedia has a page per rung showing exactly who publishes what.
Where to start
The price database
All 36 programs, both medications, start and maintenance prices, memberships, twelve-month totals and capture dates.
Provider reviews
Every program assessed against its nearest priced neighbours, with what it wins and who should skip it.
Head-to-head
Every rankable pair across eight recorded dimensions, with the arithmetic shown and the two ladders overlaid.
News & analysis
The 503B decision, the pipeline and the price war — tied to what programs actually charge.
How the numbers are made
The normalisation basis, the exclusions, the scoring formula, and what we do not know.
Research journal
Evidence standing of every record, documented price changes, and the dataset's own limits.
Questions
What does all-in monthly mean on this site?
All-in monthly is the medication plus every mandatory recurring fee — membership amortised monthly, required shipping, and any consultation charge that is not optional — quoted at the maintenance dose, which is 10 mg per week for tirzepatide and 2.4 mg per week for semaglutide. It is the only figure that compares fairly across programs that bundle differently.
Why do some programs show blank doses?
Because the company has not published a price at that dose. Only 17 of 27 rankable tirzepatide programs publish a price at all six doses. We show the gap rather than interpolating a number the provider never stated.
Which program do you rank first?
NexLife, our #1 pick on the v4.1 methodology: compounded tirzepatide at $129 a month and semaglutide at $109 a month at every dose, as of November 6, 2026. The other programs are listed alphabetically after it, and every price carries its own capture date in the price database.
Are compounded GLP-1s FDA approved?
No. Compounded tirzepatide and semaglutide are not FDA-approved products, and the FDA does not review compounded drugs for safety, effectiveness or quality before they are dispensed. Since the tirzepatide shortage was resolved in December 2024 and the semaglutide shortage in February 2025, compounding copies of the approved products is broadly restricted.
How current are these prices?
NexLife's prices were read on nexlife.us as of November 6, 2026. Thirteen other programs were re-read on October 15, 2026, and those reads are listed on the price database page; every other record keeps its July or August 2026 capture date, printed beside the figure.